(NasdaqGM:FULC), CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.(R) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of […]
(NASDAQ:ORIC), SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 3, 2025 (the “Grant Date”), ORIC granted a total of 18,400 non-qualified stock options and 3,000 restricted
(NYSE MKT:CLM),(NYSE MKT:CRF), NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — Cornerstone Strategic Investment Fund, Inc. (NYSE American: CLM) (CUSIP: 21924B302) and Cornerstone Total Return Fund, Inc. (NYSE American: CRF) (CUSIP: 21924U300), (individually the “Fund” or, collectively, the “Funds”), each a closed-end management investment company, announced that in keeping with each Fund's previously adopted monthly
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 07, 2025 Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 07, 2025 CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.(R) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 07, 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 3, 2025 (the “Grant
Cannabix Technologies announces Non-Brokered LIFE Private Placement GlobeNewswire November 07, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) announces a non-brokered private placement for a minimum of 2,127,659 units
Ultralife Corporation Files Form 12b-25 Notification of Late Filing GlobeNewswire November 07, 2025 NEWARK, N.Y., Nov. 07, 2025 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Form 10-Q for the third quarter ended
Cornerstone Funds Announce Continuing Monthly Distributions and Reset Distribution Amounts for 2026 GlobeNewswire November 07, 2025 NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — Cornerstone Strategic Investment Fund, Inc. (NYSE American: CLM) (CUSIP: 21924B302) and Cornerstone Total Return Fund, Inc. (NYSE American: CRF) (CUSIP: 21924U300), (individually the “Fund” or, collectively, the “Funds”), each a closed-end
The following issues have been halted by CIRO: Company: The INX Digital Company Inc. Cboe CA Exchange Symbol : INXD All Issues: Yes Reason: Pending Delisting Halt Time (ET): 4:00 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented